Drug updated on 4/16/2024
| Dosage Form | Tablet (oral; 20 mg, 40 mg, 60 mg, 80 mg and 120 mg) |
| Drug Class | Atypical antipsychotics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of schizophrenia in adults and adolescents (13 to 17 years).
- For the treatment of depressive episode associated with bipolar I disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy.
- For the treatment of depressive episode associated with bipolar I disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate.
Summary
- Lurasidone hydrochloride (Latuda) is indicated for the treatment of schizophrenia in adults and adolescents aged 13 to 17 years, as well as depressive episodes associated with bipolar I disorder in both adult and pediatric patients aged between 10 to 17 years.
- A systematic review comparing lurasidone with brexpiprazole and cariprazine found that a dose of lurasidone at 160 mg performed best in terms of change in Positive and Negative Syndrome Scales (PANSS) scores at six weeks, particularly when compared with brexpiprazole.
- In children and adolescents treated with antipsychotics including lurasidone, risperidone was associated with significant prolactin increase while aripiprazole was linked to significant decrease; however, despite these changes few adverse reactions were reported according to one meta-analysis study.
- Another analysis suggested that high doses (>80mg/day) of lurasidone may be beneficial for treating acute schizophrenia among Japanese patients without increasing the risk of extrapyramidal symptoms which are commonly seen side effects from antipsychotic medications.
- The drug has been evaluated through nine Systematic Reviews / Meta-Analyses studies focusing on its efficacy, safety profile, tolerability across different patient populations such as adults or children suffering from conditions like schizophrenia or bipolar depression.
- While some adverse events such as akathisia have been noted more frequently among those taking Latuda than placebo users during trials involving schizophrenic patients; overall it appears this medication can significantly improve depressive symptoms while having minimal impact on endocrine or cardiovascular systems based on available research data reviewed so far.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Latuda (lurasidone hydrochloride) Prescribing Information. | 2022 | Sunovion Pharmaceuticals Inc. Marlborough, MA |